Trametinib Boosts PFS and Response Rates in Low-Grade Ovarian Cancer

April 7, 2020 10:00 am

By Denise Myshko

Trametinib (Mekinist) monotherapy has emerged as a new treatment option for women with recurrent low-grade serous ovarian cancers based on improvements in survival outcomes and response rates demonstrated in a phase II/III study, according to David M. … Read more

Trametinib Tx Shows Promise in Tough-to-Treat LGSOC

September 30, 2019 6:00 pm

By Pam Harrison

Targeted drug provokes good response in chemoresistant, low-grade serous ovarian or peritoneal cancer.

Trametinib (Mekinist) treatment was associated with better outcomes in women with recurrent or progressive low-grade serous ovarian or peritoneal cancer versus treatment with standard-of-care … Read more